276 related articles for article (PubMed ID: 18158039)
21. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
22. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
23. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
[TBL] [Abstract][Full Text] [Related]
24. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
25. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer volume at biopsy predicts clinically significant upgrading.
Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
[TBL] [Abstract][Full Text] [Related]
27. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
28. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
[TBL] [Abstract][Full Text] [Related]
29. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
[TBL] [Abstract][Full Text] [Related]
30. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
31. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
32. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
33. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
34. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.
Mann MJ; DeCastro GJ; Desai M; Benson MC; McKiernan JM
Urology; 2008 Dec; 72(6):1203-7. PubMed ID: 18674807
[TBL] [Abstract][Full Text] [Related]
35. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
36. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
Nanda A; Chen MH; Renshaw AA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
[TBL] [Abstract][Full Text] [Related]
37. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Aigner F; Mitterberger M; Steiner E; Bartsch G; Horninger W
BJU Int; 2008 May; 101(10):1223-6. PubMed ID: 18190631
[TBL] [Abstract][Full Text] [Related]
38. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
[TBL] [Abstract][Full Text] [Related]
39. Determinants of treatment regret in low-income, uninsured men with prostate cancer.
Hu JC; Kwan L; Krupski TL; Anger JT; Maliski SL; Connor S; Litwin MS
Urology; 2008 Dec; 72(6):1274-9. PubMed ID: 18313115
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
White WM; Sadetsky N; Waters WB; Carroll PR; Litwin MS
J Urol; 2008 Dec; 180(6):2409-13; discussion 2414. PubMed ID: 18930270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
